This document discusses the benefits of Quality 10 (Q10) principles for pharmaceutical manufacturing. It emphasizes that Q10 promotes robust manufacturing processes, continual improvement, risk management, and product consistency. Q10 establishes a harmonized global language of science through clear documentation of quality systems, management responsibilities, and transparency. When properly implemented, Q10 allows for optimal resource use, increased confidence in product quality, and greater assurance and reduced risk through enhanced industry and regulator understanding.
The document discusses emerging challenges related to ICH Q8 and Q10 implementation, including increased risk and non-compliance due to process variability. It also discusses how quality inspectors and assessors can evaluate product control strategy, quality by design, manufacturing processes, and change management systems. The rest of the document focuses on knowledge management, data integrity, and quality metrics as indicators of operational reliability and quality culture. Key quality metrics discussed include lot acceptance rate, product quality complaint rate, right first time rate, invalidated OOS rate, APR/PQR on time rate, CAPA rate, and ability to initiate voluntary CAPA.
This document discusses the application of ICH Q8 and Q10 principles to pharmaceutical product development and manufacturing. It begins with an example of a dissolution failure incident to highlight the importance of understanding products and processes. It then outlines tools and approaches like knowledge management and quality risk management that can be used from development through commercial manufacturing following ICH Q8 and Q10 guidelines. Finally, it provides a case study example of how these principles were applied to the development of the drug Saxagliptin.
This document summarizes a full day workshop on quality culture for success. It discusses the importance of quality culture in ensuring product quality and safety. Quality culture is defined as an environment where everyone understands the importance of product quality and patient safety. It is the single most important indicator for delivering quality drugs. However, quality culture does not happen by accident - it must be intentionally created through relevant processes, controls, and behaviors that are understood and followed. The document provides examples of how quality culture can be measured and discusses the criticality of quality culture and how to maintain it despite pressures to reduce costs. It outlines potential symptoms and actions if an organization lacks a strong quality culture.
This document contains a summary for Vikas Singh, a Chemical Engineer with over 4 years of experience in petrochemical plant operations and planning. It lists his contact information, educational background including a Bachelors in Chemical Engineering, and work experience as Shift In Charge at Asian Paints Ltd since 2012 where he manages plant activities and production. It also outlines his core competencies such as strong engineering skills, analytical capabilities, and interpersonal skills.
This document describes the implementation of TEAMwork boards in the pediatric intensive care unit (PICU) at a children's hospital. The TEAMwork boards were developed to foster frequent problem solving and timely resolution of issues using a visual tool with red, yellow, and green sections. An example problem around critical medication IV drips was presented, showing the current state challenges and proposed future state improvements. Survey results found the boards had a positive impact and staff felt their ideas were considered. The boards promoted continuous improvement and engagement. Keys to their success included encouraging idea submission and feedback, and recognizing contributions.
Regulatory agencies prioritize manufacturing sites for inspection based on factors like probability and severity of issues, detectability of problems, site age and recall history, product usage and therapeutic importance, and risk management considerations. New sites and older sites with past recalls pose higher risks, while commonly used drugs like paracetamol present more risk than others. Effective risk management across strategic, operational, financial and compliance areas can help influence prioritization under ICH Q9 guidelines.
This document discusses the benefits of Quality 10 (Q10) principles for pharmaceutical manufacturing. It emphasizes that Q10 promotes robust manufacturing processes, continual improvement, risk management, and product consistency. Q10 establishes a harmonized global language of science through clear documentation of quality systems, management responsibilities, and transparency. When properly implemented, Q10 allows for optimal resource use, increased confidence in product quality, and greater assurance and reduced risk through enhanced industry and regulator understanding.
The document discusses emerging challenges related to ICH Q8 and Q10 implementation, including increased risk and non-compliance due to process variability. It also discusses how quality inspectors and assessors can evaluate product control strategy, quality by design, manufacturing processes, and change management systems. The rest of the document focuses on knowledge management, data integrity, and quality metrics as indicators of operational reliability and quality culture. Key quality metrics discussed include lot acceptance rate, product quality complaint rate, right first time rate, invalidated OOS rate, APR/PQR on time rate, CAPA rate, and ability to initiate voluntary CAPA.
This document discusses the application of ICH Q8 and Q10 principles to pharmaceutical product development and manufacturing. It begins with an example of a dissolution failure incident to highlight the importance of understanding products and processes. It then outlines tools and approaches like knowledge management and quality risk management that can be used from development through commercial manufacturing following ICH Q8 and Q10 guidelines. Finally, it provides a case study example of how these principles were applied to the development of the drug Saxagliptin.
This document summarizes a full day workshop on quality culture for success. It discusses the importance of quality culture in ensuring product quality and safety. Quality culture is defined as an environment where everyone understands the importance of product quality and patient safety. It is the single most important indicator for delivering quality drugs. However, quality culture does not happen by accident - it must be intentionally created through relevant processes, controls, and behaviors that are understood and followed. The document provides examples of how quality culture can be measured and discusses the criticality of quality culture and how to maintain it despite pressures to reduce costs. It outlines potential symptoms and actions if an organization lacks a strong quality culture.
This document contains a summary for Vikas Singh, a Chemical Engineer with over 4 years of experience in petrochemical plant operations and planning. It lists his contact information, educational background including a Bachelors in Chemical Engineering, and work experience as Shift In Charge at Asian Paints Ltd since 2012 where he manages plant activities and production. It also outlines his core competencies such as strong engineering skills, analytical capabilities, and interpersonal skills.
This document describes the implementation of TEAMwork boards in the pediatric intensive care unit (PICU) at a children's hospital. The TEAMwork boards were developed to foster frequent problem solving and timely resolution of issues using a visual tool with red, yellow, and green sections. An example problem around critical medication IV drips was presented, showing the current state challenges and proposed future state improvements. Survey results found the boards had a positive impact and staff felt their ideas were considered. The boards promoted continuous improvement and engagement. Keys to their success included encouraging idea submission and feedback, and recognizing contributions.
Regulatory agencies prioritize manufacturing sites for inspection based on factors like probability and severity of issues, detectability of problems, site age and recall history, product usage and therapeutic importance, and risk management considerations. New sites and older sites with past recalls pose higher risks, while commonly used drugs like paracetamol present more risk than others. Effective risk management across strategic, operational, financial and compliance areas can help influence prioritization under ICH Q9 guidelines.
ARC's Dick Hill Operator of the Future Presentation @ ARC Industry Forum 2010ARC Advisory Group
ARC's Dick Hill Operator of the Future Presentation @ ARC Industry Forum 2010 in Orlando, FL.
Which Issue are you MOST worried about
for the Future?
1. Safety and Security
2. Regulations
3. Ageing Workforce – Losing Experience
4. Product Quality
5. Asset Utilization, Availability and Life
Extension
6. Unscheduled Down-time
7. Cost Containment or Reduction
8. Competitors - Doing it Better, Faster,
Cheaper…
Answer in context to “Operator of the Future”
The document discusses gap analysis and improvement tactics for environmental, health, and safety (EH&S) programs. It outlines how an analysis can identify gaps in areas like waste management, inventory, permits, safety, and emergency response. Common issues include lacking or outdated documentation, reactive approaches, and not fully understanding regulatory requirements. The analysis also considers budget impacts and provides immediate tactics to address issues. Case studies demonstrate how onsite support programs can help organizations improve compliance, prepare for inspections, and benefit from ongoing review and updates to procedures.
The document discusses the complex regulatory landscape of pharmacovigilance and how DSA ensures a smooth journey for clients to focus on other crucial areas of product development. It lists several regulatory changes between 2012-2015 from agencies like EMA, FDA, and ICH. DSA provides compliance, regulation, and implementation solutions including a pharmacovigilance database hosted on Oracle platforms in a tier 3 data center. DSA employees are tenured life science or healthcare professionals with experience across therapeutic areas, products, and supporting over 11 global regulatory inspections.
Root Cause Analysis: Smarter Tools for Better Accuracy & SpeedSafetyChain Software
This document discusses root cause analysis for food manufacturers. It defines root cause analysis and key related terms. Common mistakes in root cause analysis are identified. Methods for performing root cause analysis including the 5 Whys technique and Ishikawa or fishbone diagrams are described. Using software can provide better accuracy and speed in root cause analysis by allowing for quicker training, trend analysis of data, and improved visibility. The importance of thorough root cause analysis is discussed for preventing future issues and demonstrating a commitment to food safety.
The document outlines a strategy for operational excellence with a focus on strategic clarity, customer focus, total employee engagement, and continuous improvement. Key elements include total productive maintenance, systematic problem solving, daily management systems, value stream management, material and information flow, quality and food safety, product and equipment innovation, and continuous skills development. Safety, health, and environmental stewardship are also prioritized.
Drug Development Solutions Distinctly for the Progressive Biopharma Ventures ...Covance
This document advertises drug development services from Covance that are designed around the client's needs and goals. It highlights personalized attention from dedicated teams, collaborative engagement through ongoing communication and technology, and access to specialized scientific and regulatory expertise to help clients navigate potential issues. Clients can choose from various solutions and services at any stage of drug development, from early research through clinical trials and regulatory approval, to fit their goals and vision.
The SHARP (Social Inclusion, Hope and Recovery Project) aims to increase social inclusion, decrease distressing symptoms, reduce relapse, promote healthy living, and enable innovative practice for people in Lambeth experiencing psychosis. The impact assessment aims to use evidence collected to reach a wider audience, determine if the project makes a difference, and challenge preconceptions to effect systems changes. Reasons for the impact assessment include looking at quality of care delivered, not just numbers, and ensuring evidence requirements are appropriate for service development.
1) Dr. Obaid Ali discussed the appropriate use of Quality Risk Management (QRM) to facilitate regulatory compliance without removing industry's obligation to adhere to requirements.
2) The document defines key terms related to quality risk management including harm, hazard, hazardous situation, risk, residual risk, severity, and detectability based on ICH Q9 and ISO 14971.
3) Regulatory observations from authorities in France, South Africa, and the US FDA are presented that highlight failures to adequately perform risk assessment and management.
University of Louisville: Improving Compliance with SiteVault eRegulatoryVeeva Systems
The University of Louisville will share how using Veeva SiteVault for managing regulatory documents is improving visibility, compliance, and speeding clinical research operations. Learn more at https://sites.veeva.com/eregulatory-clinical-trials/.
The document discusses integrating a Waters ACQUITY QDa Mass Detector into existing LC-UV systems to improve process efficiency and data confidence. It can be plugged in with zero setup, enabling quality control workflow improvement through efficient peak tracking and minimizing coelution risks. This provides mass spectral data to address regulatory requests and lack of expertise, compressing development timelines without requiring new expensive technology or too much change.
The document discusses Bayside Solutions, a company that provides staff augmentation solutions for clinical and scientific professionals. It summarizes that Bayside uses a relationship-based recruiting approach to develop a robust pool of talented professionals. It then lists some of the key services Bayside provides, including accessing top talent through proven sourcing strategies, maximizing workforce ROI, and meeting critical project deadlines. Finally, it briefly outlines some of the areas of specialization that Bayside covers, such as clinical, scientific, manufacturing, and quality.
FDA ASQ presentation metrics April 2012Doug Bryson
This document discusses metrics and how they can drive both positive and negative behaviors if not implemented properly. It provides examples of good metrics that are fact-based, objective, and focus attention on key goals like customer satisfaction and regulatory compliance. Good metrics also reflect both internal and external factors. The document outlines characteristics of effective metrics and provides examples for regulatory purposes and quality improvement. It emphasizes the importance of having metrics that are close to the problem source and drive accountability.
Survey Results: How did Professionals Rank the Difficulty of eCQMs?Medisolv, Inc.
Medisolv recently surveyed a group of medical professionals to find out just how difficult the eCQM process has been for their hospital over the years.
This document discusses the challenges medical device companies face with documentation needs increasing for new product launches and global markets while facing stringent FDA regulations. It introduces Novatek as a company that can plan, design, develop, produce and maintain all necessary documentation for medical device companies, including instructions for use, labeling, user manuals, service manuals and translations. Novatek also provides quality system process documentation to help companies stay compliant and avoid potential FDA audits or consent decrees that could significantly impact their bottom line. Hiring Novatek can help companies meet product launch dates on time, ensure regulatory compliance, shorten time to market and lower translation costs.
We test the quality of your health surveyKeith Meadows
QuestReview is a new diagnostic tool that identifies issues with the quality of survey questionnaires before they are fielded. It tests survey questionnaires, identifies errors, and provides feedback to improve the questionnaire. It measures attributes like question wording, response options, reading ease, length, routing logic, difficulty, and estimated completion time. For one project, it found the Flesch Reading Score was high but some question word lengths exceeded recommendations. It also identified some complex words used.
1) Corrective action is important for customer satisfaction, profits, and ISO compliance. It helps reduce scrap, rework, and inefficiencies.
2) Weak corrective action processes can fail to properly involve people, utilize problem solving skills, consider costs, or follow through on verifying solutions.
3) Effective corrective action requires a clear problem statement, interim containment actions, root cause analysis, permanent corrective actions, and verification that the problem has been resolved.
BlueScape Environmental is an air quality and environmental consulting firm that provides services such as air permitting, emissions modeling, greenhouse gas management, and compliance support. They aim to understand clients' businesses and industries to deliver innovative solutions. BlueScape draws on in-house expertise and strategic partnerships to assist clients in addressing air quality issues and regulations effectively.
Suprasai Pharma Technology is a pharmaceutical consulting firm established in 2014 in India. It provides product development, quality assurance, and regulatory support services to help clients meet stringent pharmaceutical regulations. Suprasai strives to develop long-term relationships with clients based on integrity, professionalism, and trust. The company's vision is to conduct business ethically and help clients develop products across therapeutic areas like CNS, cardiovascular, anti-infectives and more.
The document outlines the key skills required of a software tester, including analytical and logical thinking, the ability to envision business situations, intellectual curiosity and creativity, a global approach to consider multiple stakeholders, critical thinking, applying fundamental knowledge, continuing to learn, planning and time management, effective communication, and respect for truth and integrity. It provides details on each skill area and emphasizes the importance of analysis, envisioning complex problems, asking questions, dealing with complex systems, impartial thought, applying knowledge to test situations, adapting to change, thorough planning, clear communication, and examining software with focus and integrity.
The document provides details on conducting quality audits, including:
1) An overview of audit preparation such as developing an audit plan, selecting auditors, and preparing documentation for review.
2) Guidelines for performing the audit such as conducting an opening meeting, touring the site, reviewing documentation, and holding a daily wrap-up meeting.
3) Details on audit techniques including asking questions, classifying observations, and conducting a close-out meeting to discuss audit findings.
The document outlines the key aspects of conducting a quality auditing training course, including:
1) The background and basics of auditing, types of audits, auditor conduct and necessary skills, audit preparation and planning, performing the audit, and developing an audit report and follow up.
2) It discusses the importance of effective communication, maintaining objectivity and professionalism, and properly preparing, planning and executing audits.
3) The document provides guidance on selecting auditors, developing an audit plan and schedule, preparing checklists and understanding the audit site prior to the audit.
ARC's Dick Hill Operator of the Future Presentation @ ARC Industry Forum 2010ARC Advisory Group
ARC's Dick Hill Operator of the Future Presentation @ ARC Industry Forum 2010 in Orlando, FL.
Which Issue are you MOST worried about
for the Future?
1. Safety and Security
2. Regulations
3. Ageing Workforce – Losing Experience
4. Product Quality
5. Asset Utilization, Availability and Life
Extension
6. Unscheduled Down-time
7. Cost Containment or Reduction
8. Competitors - Doing it Better, Faster,
Cheaper…
Answer in context to “Operator of the Future”
The document discusses gap analysis and improvement tactics for environmental, health, and safety (EH&S) programs. It outlines how an analysis can identify gaps in areas like waste management, inventory, permits, safety, and emergency response. Common issues include lacking or outdated documentation, reactive approaches, and not fully understanding regulatory requirements. The analysis also considers budget impacts and provides immediate tactics to address issues. Case studies demonstrate how onsite support programs can help organizations improve compliance, prepare for inspections, and benefit from ongoing review and updates to procedures.
The document discusses the complex regulatory landscape of pharmacovigilance and how DSA ensures a smooth journey for clients to focus on other crucial areas of product development. It lists several regulatory changes between 2012-2015 from agencies like EMA, FDA, and ICH. DSA provides compliance, regulation, and implementation solutions including a pharmacovigilance database hosted on Oracle platforms in a tier 3 data center. DSA employees are tenured life science or healthcare professionals with experience across therapeutic areas, products, and supporting over 11 global regulatory inspections.
Root Cause Analysis: Smarter Tools for Better Accuracy & SpeedSafetyChain Software
This document discusses root cause analysis for food manufacturers. It defines root cause analysis and key related terms. Common mistakes in root cause analysis are identified. Methods for performing root cause analysis including the 5 Whys technique and Ishikawa or fishbone diagrams are described. Using software can provide better accuracy and speed in root cause analysis by allowing for quicker training, trend analysis of data, and improved visibility. The importance of thorough root cause analysis is discussed for preventing future issues and demonstrating a commitment to food safety.
The document outlines a strategy for operational excellence with a focus on strategic clarity, customer focus, total employee engagement, and continuous improvement. Key elements include total productive maintenance, systematic problem solving, daily management systems, value stream management, material and information flow, quality and food safety, product and equipment innovation, and continuous skills development. Safety, health, and environmental stewardship are also prioritized.
Drug Development Solutions Distinctly for the Progressive Biopharma Ventures ...Covance
This document advertises drug development services from Covance that are designed around the client's needs and goals. It highlights personalized attention from dedicated teams, collaborative engagement through ongoing communication and technology, and access to specialized scientific and regulatory expertise to help clients navigate potential issues. Clients can choose from various solutions and services at any stage of drug development, from early research through clinical trials and regulatory approval, to fit their goals and vision.
The SHARP (Social Inclusion, Hope and Recovery Project) aims to increase social inclusion, decrease distressing symptoms, reduce relapse, promote healthy living, and enable innovative practice for people in Lambeth experiencing psychosis. The impact assessment aims to use evidence collected to reach a wider audience, determine if the project makes a difference, and challenge preconceptions to effect systems changes. Reasons for the impact assessment include looking at quality of care delivered, not just numbers, and ensuring evidence requirements are appropriate for service development.
1) Dr. Obaid Ali discussed the appropriate use of Quality Risk Management (QRM) to facilitate regulatory compliance without removing industry's obligation to adhere to requirements.
2) The document defines key terms related to quality risk management including harm, hazard, hazardous situation, risk, residual risk, severity, and detectability based on ICH Q9 and ISO 14971.
3) Regulatory observations from authorities in France, South Africa, and the US FDA are presented that highlight failures to adequately perform risk assessment and management.
University of Louisville: Improving Compliance with SiteVault eRegulatoryVeeva Systems
The University of Louisville will share how using Veeva SiteVault for managing regulatory documents is improving visibility, compliance, and speeding clinical research operations. Learn more at https://sites.veeva.com/eregulatory-clinical-trials/.
The document discusses integrating a Waters ACQUITY QDa Mass Detector into existing LC-UV systems to improve process efficiency and data confidence. It can be plugged in with zero setup, enabling quality control workflow improvement through efficient peak tracking and minimizing coelution risks. This provides mass spectral data to address regulatory requests and lack of expertise, compressing development timelines without requiring new expensive technology or too much change.
The document discusses Bayside Solutions, a company that provides staff augmentation solutions for clinical and scientific professionals. It summarizes that Bayside uses a relationship-based recruiting approach to develop a robust pool of talented professionals. It then lists some of the key services Bayside provides, including accessing top talent through proven sourcing strategies, maximizing workforce ROI, and meeting critical project deadlines. Finally, it briefly outlines some of the areas of specialization that Bayside covers, such as clinical, scientific, manufacturing, and quality.
FDA ASQ presentation metrics April 2012Doug Bryson
This document discusses metrics and how they can drive both positive and negative behaviors if not implemented properly. It provides examples of good metrics that are fact-based, objective, and focus attention on key goals like customer satisfaction and regulatory compliance. Good metrics also reflect both internal and external factors. The document outlines characteristics of effective metrics and provides examples for regulatory purposes and quality improvement. It emphasizes the importance of having metrics that are close to the problem source and drive accountability.
Survey Results: How did Professionals Rank the Difficulty of eCQMs?Medisolv, Inc.
Medisolv recently surveyed a group of medical professionals to find out just how difficult the eCQM process has been for their hospital over the years.
This document discusses the challenges medical device companies face with documentation needs increasing for new product launches and global markets while facing stringent FDA regulations. It introduces Novatek as a company that can plan, design, develop, produce and maintain all necessary documentation for medical device companies, including instructions for use, labeling, user manuals, service manuals and translations. Novatek also provides quality system process documentation to help companies stay compliant and avoid potential FDA audits or consent decrees that could significantly impact their bottom line. Hiring Novatek can help companies meet product launch dates on time, ensure regulatory compliance, shorten time to market and lower translation costs.
We test the quality of your health surveyKeith Meadows
QuestReview is a new diagnostic tool that identifies issues with the quality of survey questionnaires before they are fielded. It tests survey questionnaires, identifies errors, and provides feedback to improve the questionnaire. It measures attributes like question wording, response options, reading ease, length, routing logic, difficulty, and estimated completion time. For one project, it found the Flesch Reading Score was high but some question word lengths exceeded recommendations. It also identified some complex words used.
1) Corrective action is important for customer satisfaction, profits, and ISO compliance. It helps reduce scrap, rework, and inefficiencies.
2) Weak corrective action processes can fail to properly involve people, utilize problem solving skills, consider costs, or follow through on verifying solutions.
3) Effective corrective action requires a clear problem statement, interim containment actions, root cause analysis, permanent corrective actions, and verification that the problem has been resolved.
BlueScape Environmental is an air quality and environmental consulting firm that provides services such as air permitting, emissions modeling, greenhouse gas management, and compliance support. They aim to understand clients' businesses and industries to deliver innovative solutions. BlueScape draws on in-house expertise and strategic partnerships to assist clients in addressing air quality issues and regulations effectively.
Suprasai Pharma Technology is a pharmaceutical consulting firm established in 2014 in India. It provides product development, quality assurance, and regulatory support services to help clients meet stringent pharmaceutical regulations. Suprasai strives to develop long-term relationships with clients based on integrity, professionalism, and trust. The company's vision is to conduct business ethically and help clients develop products across therapeutic areas like CNS, cardiovascular, anti-infectives and more.
The document outlines the key skills required of a software tester, including analytical and logical thinking, the ability to envision business situations, intellectual curiosity and creativity, a global approach to consider multiple stakeholders, critical thinking, applying fundamental knowledge, continuing to learn, planning and time management, effective communication, and respect for truth and integrity. It provides details on each skill area and emphasizes the importance of analysis, envisioning complex problems, asking questions, dealing with complex systems, impartial thought, applying knowledge to test situations, adapting to change, thorough planning, clear communication, and examining software with focus and integrity.
The document provides details on conducting quality audits, including:
1) An overview of audit preparation such as developing an audit plan, selecting auditors, and preparing documentation for review.
2) Guidelines for performing the audit such as conducting an opening meeting, touring the site, reviewing documentation, and holding a daily wrap-up meeting.
3) Details on audit techniques including asking questions, classifying observations, and conducting a close-out meeting to discuss audit findings.
The document outlines the key aspects of conducting a quality auditing training course, including:
1) The background and basics of auditing, types of audits, auditor conduct and necessary skills, audit preparation and planning, performing the audit, and developing an audit report and follow up.
2) It discusses the importance of effective communication, maintaining objectivity and professionalism, and properly preparing, planning and executing audits.
3) The document provides guidance on selecting auditors, developing an audit plan and schedule, preparing checklists and understanding the audit site prior to the audit.
The document provides details on conducting quality audits, including:
1) An overview of audit preparation such as developing an audit plan, selecting auditors, and preparing the auditees.
2) Guidelines for performing the audit such as conducting an opening meeting, touring the site, questioning techniques, and daily wrap-ups.
3) Details on audit report out including classifying observations as critical, major, or minor and conducting a close-out meeting.
This document discusses quality auditing in the pharmaceutical industry. It defines quality auditing and explains that it involves systematically examining quality systems to determine compliance. The document outlines different types of audits including internal, external, regulatory, product, process, and system audits. It discusses planning, conducting, and reporting on audits. The key objectives of audits are to ensure quality, assess effectiveness of quality assurance systems, and permit timely correction of any issues. Audits help build confidence in quality management practices and identify areas for improvement.
PECB Webinar: Conducting Effective Quality System AuditsPECB
The webinar covers:
• Principles of auditing
• Attributes of effective auditors
• Audit aftermath-communicating audit results, ensuring effective closure of non-conformities
Presenter:
This webinar was presented by Cyrus Karanja, Systems Co-ordinator at Tetra Pak and a well-practiced professional with over 9 years of experience in the areas of Quality, Health, Safety & Environmental Management.
Link of the recorded session published on YouTube: https://youtu.be/aUcvt2-x8PM
A test strategy is the set of ideas that guides your test design. It's what explains why you test this instead of that, and why you test this way instead of that way. Strategic thinking matters because testers must make quick decisions about what needs testing right now and what can be left alone. You must be able to work through major threads without being overwhelmed by tiny details. James Bach describes how test strategy is organized around risk but is not defined before testing begins. Rather, it evolves alongside testing as we learn more about the product. We start with a vague idea of our strategy, organize it quickly, and document as needed in a concise way. In the end, the strategy can be as formal and detailed as you want it to be. In the beginning, though, we start small. If you want to focus on testing and not paperwork, this approach is for you.
Faculty of Business and LawAssignment BriefModule Title.docxRAJU852744
Faculty of Business and Law
Assignment Brief
Module Title:
Contemporary Issues in HR Service Deliver
Assignment Number
1
Module Code:
202HRM
Assignment Title
Allocation of HR Service Delivery in SME case study
Assignment Weighting
50%
Release Date:
23/01/17
Module Leader
Konstantinos Kakavelakis
Submission Date/Time:
16/03/17 :
23:55:00
Submission
Time and Place:
Submission through Turnitin ONLY
Assessment Information
This assignment is designed to assess learning outcomes:
1.
Understand the reasons behind organisations changing the structure and location of HR service provision.
2.
Understand the different HR service delivery models available to contemporary organisations.
3.
Understand the challenges involved in maintaining and managing HR services and how standards are established and monitored.
This assignment is an individual assignment.
This assignment requires you to:
Company Case Study: Softwire
Who We Are
Softwire is a UK-based software development company with offices in London and Bristol.
Our highly talented and dedicated staff deliver work of exceptional quality, and can help you no matter what stage you are at in developing your software. We are totally committed to customer satisfaction, and this drives everything we do.
Customer Satisfaction
Softwire is a complete software partner for our clients, from initial consultancy and design phases right through to deployment and ongoing support. We can provide a one-stop shop for your project through our partnerships with trusted third parties such as web designers and ISPs. Our proactive and capable project managers run project smoothly and efficiently, leaving you with an exceptional software solution for a highly competitive price.
We have experience of a vast range of markets and technologies and are continually broadening our horizons yet further. Our can-do attitude and deep technical experience allow us to deliver the most challenging projects with a minimum of fuss.
Website -
http://www.softwire.com/
Scenario
In building up the company, the founders of Softwire have always valued the contribution of its employees to its success.
Currently, all HR services are performed by the foundering members.
They have decided recently that it is now time to invest in a small team of employees to enable the company to extent its existing HRM services.
The founders wish to retain some HRM services internally but also to consider outsourcing other HRM services.
One of the founders, has agreed to produce a report outlining the company’s plans on this issue.
Task
Imagine then that you are the member of the team with the task of producing this report.
The report will illustrate:
·
a brief outline and justification of your view of HR service delivery (i.e. generalist/specialist. centralised/decentralised).
·
identification and justification of what HR services would be retained and what HR services would be outsourced.
Your discussion should d ...
The document discusses qualities of good testers, noting that they practice epistemology and have skills like critical thinking. Good testers have attitudes of being cautious, curious, and critical. Soft skills are also important for testers, including skills like communication, time management, and maintaining a positive attitude.
STAT4610 Project 5So You Want to be an Entrepreneur”INTROD.docxmckellarhastings
STAT4610 Project 5
“So You Want to be an Entrepreneur?”
INTRODUCTION
Starting a new business can be an exciting adventure! Who doesn’t want to find themselves at the top of the next Microsoft, Apple, Facebook, Myspace, Instagram, Beanie Babies, Pet Rocks, Roto-Rooter, Enron, WorldCom, (OK, you get the point!)?
The problem with starting a new business is it carries an inherent amount of risk. (OK, a considerable amount of risk!) One-third of businesses fail within the first two years, and over half are gone in five years. That’s a waste of a significant amount of toil, sweat, intellectual effort, creativity, and—oh yes—capital! Failed businesses have stripped entrepreneurs of their life savings (and the savings of others) for millennia, but the successes have also lined the pockets of a lot of savvy investors.
Since most people can’t afford to fund their own startups, a popular strategy involves convincing others to get behind your great idea. Venture capital funds are always willing to chase the next big thing, but unfortunately there is a limit to the patience of the world’s check-writers, and most of them didn’t get rich without recognizing when it is time to cut losses.
There is hope, however! Analytics can help every new business set realistic expectations for their investors, and in fact are essential in the formulation of a business plan. Because of the uncertainties involved with startups (in terms of costs, timelines, returns, rates of success, etc.) it is often difficult to forecast the progression of a new venture, but with a sufficient knowledge of the field and the tasks required, a simulation can frequently get an entrepreneur into the right ballpark. Sometimes this is enough to start the money flowing!
PROJECT OVERVIEW
In this project you will develop a business plan for an Angel Investor in order to secure funding for your new startup. You will require funding until the point that your company generates a profit and is actually able to return capital (or positive equity) to its investors. Expenses may include payroll for developers or designers, facilities and infrastructure, marketing and sales, purchasing or collecting data, research, and a variety of other costs that you may want to identify. Obviously, you will have to identify a viable product around which to build your company, and if you’re stuck without an idea, feel free to go back to your Gateway Course and build a business around app development. Finally, you will need to determine the cost of executing your business plan across this timeline in order to secure sufficient funding.
[As an aside, the particular product or service is not essential to this project—you may use something developed in another course, some cool idea that you might have in mind, or something entirely fictional.]
You may make any assumptions you want concerning the availability of personnel (whether you will be required to hire them or if they are already onboard as part .
The document provides an overview of information security audits from an expert's perspective. It discusses how to prepare for an audit, what to expect during each phase, how to communicate with auditors, and tips for passing the audit, including having proper documentation, controls, policies, and management support. The goal is for the audit to be a learning experience and opportunity to improve the security program rather than a failure.
The document discusses various topics relating to quality audits, including definitions, the purpose and types of audits, auditor skills and conduct, and potential problems auditors may encounter. It defines key terms like assessment, audit, compliance, and defines a quality audit. It outlines the purpose of audits is to provide objective feedback to enable management decisions. It also discusses auditor skills like competence, communication, listening, independence, observation, objectivity, and judging. Finally, it discusses problems like antagonism, time wasters, evasiveness, sympathy, glossing, and bribery and how auditors should address them.
Drug Development in Today's Regulatory EnvironmentMichael Swit
Webinar sponsored by NanoTecNexus (www.http://nanotecnexus.org/) on contemporary regulatory issues in drug development, with an emphasis on:
Overall Planning
Working With FDA
Clinical Trial Execution
CMC Issues
Safety Issues
Labeling
Ingredients – Active And Inactive
Having a Prosperous New Year with Your CRO: The Gift of a Great Contract!mwright1
The document discusses key considerations for clinical trial contracts between sponsors and contract research organizations (CROs). It notes that:
1) The CRO industry is large and growing, taking on more of the research and development expenditures of pharmaceutical companies. Contracts must carefully define responsibilities to ensure expectations are met.
2) Data ownership, security, and management are important issues to address. Sponsors will want ownership and control over trial data specific to their drug or device.
3) Confidentiality is paramount, as intellectual property is highly valuable in the life sciences industry. Contracts must specify what information is confidential and how it will be protected.
The document discusses the key characteristics of scientific research, including:
1. Purposiveness - Research is conducted with a clear purpose or aim, such as investigating how to increase employee commitment.
2. Rigor - Research uses rigorous methodology, such as developing hypotheses and collecting data systematically.
3. Testability - Hypotheses are tested using statistical analysis and data collected.
The document provides examples to illustrate these key aspects of scientific research methodology.
The document announces a two-day in-person seminar on preparing for and responding to FDA inspections. The seminar will be held on July 21st and 22nd, 2016 in Cape Town, South Africa and led by regulatory expert David Dills. It will provide fundamentals and best practices for interacting with inspectors, ensuring documentation is in order, responding to inspection findings, and achieving favorable outcomes. Topics include inspection preparation and training, documentation requirements, dos and don'ts for interacting with investigators, and following up after inspections.
I probably should have titled this section Who Ensures that Digita.docxsalmonpybus
I probably should have titled this section Who Ensures that Digital Health Tools are Safe?. The Food and Drug Administration (FDA) is largely tasked with ensuring the safety and oversight of "traditional" medical devices. Consumer oriented technologies and many of the digital health tools available today present a more unique challenge for federal regulators. For example, software which reads digital mammograms is clearly a medical device intended to diagnose cancer. However, a mobile application which a user/consumer/patient leverages to track daily blood glucose levels is a very different approach. The mobile application is not making a diagnosis. There is limited risk of harm or change in medical management resulting from use. To address many of these nuances the FDA has created a
digital health resource page. The FDA often issues regulatory guidance documents in the event there is a question surrounding the legal authority provide oversight on a specific tool, device, or software component of a device.
FDA Approach to Risk
The FDA continues to evaluate technologies in the context of risk and classifies technologies in one of three tiers. It is important to note that any mobile app; regardless of if FDA approval is needed or not; may be submitted to the FDA for review. At times a vendor will submit to the FDA for review to increase the marketability of service or solution. The device itself is not required to be evaluated but the vendor chooses to do so anyway. The classes fall into one of the three following categories:
Class I - Low-risk where general reporting of adverse events occurs
Class II - Medium-risk where the FDA must provide review and clearance before marketing of the solution occurs. Review period takes between 60 to 90 days.
Class III - High risk where clearance before marketing must be obtained and the clearance must involve clinical studies showing that the product is safe and effective.
Mobile Medical Applications
The FDA has done a good job of clarifying the types of mobile apps that will not, will, and may be regulated by providing guidance documents. The FDA calls this document
Mobile Medical Applications Guidance. The aim of the guidance document is to clarify where the agency intends to enforce oversight and where the agency will continue to monitor developments. While the guidance document and website is extensive, there are a few key items worth mentioning. 1. The FDA defines what mobile medical applications
ARE. They can be Apps or accessory devices which meet the definition of a medical device (somewhat abridged and abbreviated for simplicity)- recognized by the National Formulary (ie Pharmaceuticals), intended for the use in the diagnosis of disease, cure, mitigation, treatment, or prevention of disease; or affect the structure or function of the body of man or other animals. 2. Consumers can use both medical apps and mobile apps to manage their o.
The document provides information on how to craft an effective clinical research associate (CRA) resume, highlighting the services of BestResumeHelp.com which includes industry expertise, customization, keyword optimization, and professional formatting to showcase a CRA's qualifications and help secure new career opportunities in clinical research. The process involves placing an order, collaborating with resume experts, reviewing drafts and making revisions, and receiving the finalized resume. Key skills and responsibilities for CRAs include ensuring regulatory compliance, protocol adherence, data accuracy, and subject safety across clinical trials.
Useful presentation from Sue Kellaway which focuses on Line Manager recruitment refresher training. It can be delivered in four hours which is great for time pressed Managers!
This document provides information on standard operating procedures (SOPs) for manufacturing equipment used in liquid, solid, and semi-solid dosage forms. It discusses what an SOP is, the objectives and benefits of SOPs, types of SOPs, SOP writing style, important points to consider when writing SOPs, and common equipment used to prepare liquid and semi-solid formulations. The document emphasizes that SOPs are essential for ensuring consistent, compliant production operations and for training personnel. They help maintain quality control and assure regulatory compliance.
Similar to Importance of Opening Presntation in Inspection Process (20)
The document discusses anti-thymocyte globulin (ATG), which is used for acute organ rejection. ATG is produced from rabbits that are inoculated with human T lymphocytes to trigger an antibody response. The antibodies produced in rabbits are then extracted, purified, and administered to patients to kill arrays of lymphocytes. Developing a process to characterize the target globulin and transferring knowledge will help establish protein production. Key challenges include maintaining clean environments and aseptic extraction, purification, and filling processes.
The document discusses establishing the OR Centre for Quality Sciences to provide consulting services to the pharmaceutical and biologics industries regarding quality, regulatory affairs, innovation, and technology. It aims to engage subject matter experts to support academia, industry, and government. The Centre will focus on shifting from a compliance to a quality culture and aligning with new regulatory expectations in a changing technological landscape with advances in areas like artificial intelligence and data sciences. It will provide training, reviews, audits, and other services to support quality systems, documentation practices, regulatory submissions, clinical trials, and more.
An article on contamination of Diethylene Glycol in Pharmaceuticals. Thanks to Dr. Ajaz S. Hussain for all teaching, sharing knowledge and supporting in professional development.
The document announces a training on demonstrating a quality management system during inspections to be held on September 30, 2023 in Kotri, Sindh. It will provide participants with techniques for showcasing compliance and procedures when regulatory audits occur. A list of attendees is included but not summarized for brevity.
The document provides tips for demonstrating a quality management system during an inspection. It advises being simple, clear, truthful, and confident when welcoming inspectors. Assign specific duties to staff and have flexibility. Listen fully to questions before responding, and don't argue - say you will look into issues. Practice mock inspections, recognize potential problems, and maintain your system daily.
The document discusses the services provided by the Centre for Quality Sciences, which include designing new and upgrading existing pharmaceutical manufacturing facilities, conducting GMP audits and training, assisting with regulatory submissions, and providing consulting services regarding quality systems, data integrity, and compliance strategies. The Centre's vision is to shift the industry towards a quality culture through knowledge sharing and facilitating discussions to develop strategic roadmaps. It aims to help companies strengthen quality compliance and sustain their quality management systems in the changing regulatory landscape.
The document discusses biomarkers, which are measurable indicators of biological states or conditions. It describes biomarkers as tools that can help facilitate medical product development. The document outlines different types, categories, and descriptions of biomarkers. It discusses how biomarkers can be qualified and approved by regulatory agencies like the FDA for specific contexts of use. The document provides examples of biomarkers that have been used for various purposes, such as assessing disease diagnosis, treatment effectiveness, and safety. It also summarizes some biomarkers that have been qualified or considered for qualification by the FDA.
1) The document discusses the evolution of ensuring drug quality from relying solely on testing to emphasizing proper manufacturing processes and controls.
2) It explains that without understanding the entire manufacturing process, one cannot say a drug is consistent in quality and purity or free of contamination.
3) Current good manufacturing practices (cGMP) help assure drug safety and efficacy by requiring facilities to control manufacturing operations through quality management systems and robust operating procedures.
The document discusses neurotoxicity and neurodegeneration in drug development. It notes that safety issues, especially related to the cardiovascular system and central nervous system, are among the most common reasons for drug development failure. Biomarkers for early detection of potential neurotoxicity could help improve success rates by facilitating safety screening earlier in the development process. The central nervous system is particularly vulnerable, as neurotoxicity is a frequent cause of failure in both pre-clinical and clinical phases of development.
Mr. Atiq ur Rahman has over 27 years of experience in pharmaceutical manufacturing and supply chain management. He has expertise in facility design, quality audits, and regulatory compliance. More recently, he has worked on data engineering, data acquisition, and applying data science concepts in pharmaceutical and other process industries. The presentation provides an overview of the industrial revolutions from Industry 1.0 to 5.0 and defines Pharma 4.0 as the convergence of people, systems, and data within a singular network powered by artificial intelligence. It discusses strategies for digital transformation and achieving digital maturity, including evaluating current technology needs and creating a roadmap with goals and timelines.
The document discusses the relationship between PIC/S and ICH and their roles in harmonizing GMP standards globally. PIC/S focuses specifically on GMP inspections and developing harmonized GMP standards and training inspectors. ICH focuses more broadly on safety, efficacy, quality and regulatory guidelines. Together they aim to promote reliance between regulatory authorities and open doors of trust through mutual recognition agreements and understanding of inspection systems. The document provides a comprehensive overview of their goals and collaboration to harmonize standards for patients worldwide.
The document discusses a presentation on quality issues observed by the FDA during inspections of pharmaceutical facilities in 2022. It notes the FDA observed deficiencies related to lack of written SOPs, insecure data, failure to investigate out of specification results, cleaning issues, and missing environmental monitoring programs. The document also presents a case study of a facility that had a significant media fill failure in November 2021 but did not initiate a recall until April 2022, exposing patients to risk. It describes poor aseptic techniques observed by FDA investigators during manufacturing operations.
The filling machine and HEPA filter located directly above the filling machine in the filling room were significantly discolored with an unknown substance. This indicates potential contamination issues that need to be investigated and addressed. Facilities should ensure machinery and equipment are properly cleaned and maintained to prevent contamination that could compromise product quality.
The document discusses the pressure of real-world evidence on pharmaceutical regulatory science. It mentions the author's experience interacting with international regulatory agencies like the FDA, EU, Health Canada, and MHRA. It lists some references on topics like continuous manufacturing and real-time dissolution prediction. The document emphasizes that improving individual parts of a system will not improve the overall system, and that a systems approach to quality is needed.
This document provides information about an upcoming training session on Good Manufacturing Practices. The session will be held on October 16th in Karachi and will run from 9:00 am to 3:00 pm. It is aimed at pharmaceutical professionals with backgrounds in pharmacy, chemistry, microbiology and related fields. Experts from the US pharmaceutical industry will discuss advancements in manufacturing technology and emerging regulatory changes. The session will include tutorials, discussions, and Q&A to help participants better understand GMP requirements and ensure quality assurance. Participants will pay Rs. 10,000 or Rs. 5,000 depending on whether they are attending as part of their job. More details and contact information are provided.
This document contains questions and answers related to pharmaceutical quality and manufacturing. It discusses topics like clean hold time, dirty hold time, contamination control strategies, particles in injections, the differences between CMC, GMP, and continuous manufacturing. It also addresses questions about PIC/S, such as whether they issue membership, if inspections by one country are accepted by others, and that GMP certificates are issued by individual regulatory authorities rather than PIC/S.
This document discusses issues that may arise with generic drugs compared to innovator drugs. Bioequivalence studies only show equivalence at a single point in time and do not guarantee equivalence over the lifetime of the drug. Manufacturing the drug involves many variables like people, equipment, materials that could result in potency and dissolution differences compared to the innovator. The document provides data that showed increased hospitalization rates for certain generics compared to the innovator drug. It emphasizes the need for consistent quality manufacturing to ensure patient safety.
The document discusses several topics related to improving drug quality including:
1) Evidence from clinical trials and real world use is key to determining drug effectiveness but quality can deteriorate after marketing authorization without a strong quality management system.
2) Errors must be eliminated through quality by design in development and operational excellence, and companies must continuously improve rather than just fixing problems.
3) Digital transformation, identifying critical quality attributes, and moving to more flexible and integrated quality systems will help address issues and improve patient outcomes.
This document appears to be a scanned receipt from a restaurant in New York City listing various food and drink items purchased, with a subtotal of $86.62 and total including tax of $97.45. The receipt details a variety of appetizers, entrees, drinks and desserts ordered for multiple guests.
This document discusses key elements of good manufacturing practices (GMP) for pharmaceutical manufacturing. It covers topics like building layout, equipment, utilities, documentation, materials, production processes, packaging, quality systems, facilities, laboratories and ensuring the safety, efficacy and quality of pharmaceutical products. The overall message is that GMP provides a foundation and framework to establish process and quality control, validate operations, continuously improve and ultimately ensure that pharmaceutical products meet their intended quality standards.
Impact of Effective Performance Appraisal Systems on Employee Motivation and ...Dr. Nazrul Islam
Healthy economic development requires properly managing the banking industry of any
country. Along with state-owned banks, private banks play a critical role in the country's economy.
Managers in all types of banks now confront the same challenge: how to get the utmost output from
their employees. Therefore, Performance appraisal appears to be inevitable since it set the
standard for comparing actual performance to established objectives and recommending practical
solutions that help the organization achieve sustainable growth. Therefore, the purpose of this
research is to determine the effect of performance appraisal on employee motivation and retention.
Ganpati Kumar Choudhary Indian Ethos PPT.pptx, The Dilemma of Green Energy Corporation
Green Energy Corporation, a leading renewable energy company, faces a dilemma: balancing profitability and sustainability. Pressure to scale rapidly has led to ethical concerns, as the company's commitment to sustainable practices is tested by the need to satisfy shareholders and maintain a competitive edge.
Colby Hobson: Residential Construction Leader Building a Solid Reputation Thr...dsnow9802
Colby Hobson stands out as a dynamic leader in the residential construction industry. With a solid reputation built on his exceptional communication and presentation skills, Colby has proven himself to be an excellent team player, fostering a collaborative and efficient work environment.
Designing and Sustaining Large-Scale Value-Centered Agile Ecosystems (powered...Alexey Krivitsky
Is Agile dead? It depends on what you mean by 'Agile'. If you mean that the organizations are not getting the promised benefits because they were focusing too much on the team-level agile "ways of working" instead of systemic global improvements -- then we are in agreement. It is a misunderstanding of Agility that led us down a dead-end. At Org Topologies, we see bright sparks -- the signs of the 'second wave of Agile' as we call it. The emphasis is shifting towards both in-team and inter-team collaboration. Away from false dichotomies. Both: team autonomy and shared broad product ownership are required to sustain true result-oriented organizational agility. Org Topologies is a package offering a visual language plus thinking tools required to communicate org development direction and can be used to help design and then sustain org change aiming at higher organizational archetypes.
12 steps to transform your organization into the agile org you deservePierre E. NEIS
During an organizational transformation, the shift is from the previous state to an improved one. In the realm of agility, I emphasize the significance of identifying polarities. This approach helps establish a clear understanding of your objectives. I have outlined 12 incremental actions to delineate your organizational strategy.
A presentation on mastering key management concepts across projects, products, programs, and portfolios. Whether you're an aspiring manager or looking to enhance your skills, this session will provide you with the knowledge and tools to succeed in various management roles. Learn about the distinct lifecycles, methodologies, and essential skillsets needed to thrive in today's dynamic business environment.
A team is a group of individuals, all working together for a common purpose. This Ppt derives a detail information on team building process and ats type with effective example by Tuckmans Model. it also describes about team issues and effective team work. Unclear Roles and Responsibilities of teams as well as individuals.
Originally presented at XP2024 Bolzano
While agile has entered the post-mainstream age, possibly losing its mojo along the way, the rise of remote working is dealing a more severe blow than its industrialization.
In this talk we'll have a look to the cumulative effect of the constraints of a remote working environment and of the common countermeasures.
Importance of Opening Presntation in Inspection Process
1. Inspection: A Challenge or Opportunity (Writing Series - 01)
Opening Presentation: Let’s start to demonstrate the Quality System efficiently
Obaid Ali, R. Ph., M. Phil. Ph. D.
Deputy Director/ Civil Service Officer
(Karachi the 30th
Sept, 2017)
The word audit is originated from an old Greek word used to verify the accounts maintained in the register.
Journey from verification to assessment followed by investigation have a long history to emphasize inspection
process as one of the fundamental and inevitable tool where question of human protection arises.
Good Manufacturing Practices (Pre-approval, post-approval, regular compliance and for cause) inspection of your
drug manufacturing facility is a real time expanding challenge in this emerging world because different inspectors
of different countries and sometimes of the same country came in with different approaches. The one most
common practice that certainly derived from their principle / policy / procedure is to hear from your own opening
presentation. Let me advice you, it is a very important and crucial time that may navigate inspector(s) to drive in.
Be prepared and do work hard to make this presentation responsive, impressive and based on facts. Do not waste
time in discussing things that may not attract the inspector’s interest and attention. Please understand why the
inspector is at your facility and what he or she needs to know. Your first presentation may germinate the seed of
thinking to travel and grow across the boundary that you may influence in designing. It is advised to please make
a framework that encourage thinking process across the all operations to participate in designing and developing
the opening presentation. Enough pre discussion on the presentation and practice should be conducted both to
have a critical review and making it worthy enough. In this way you will be able to deliver the messages in
simple, clear and pictorial language more efficiently. Logical elucidations of subject certainly strengthen the
confidence and create space in the long lasting memories and minds of inspector(s). It is suggested not going
beyond 20 minutes leaving another time span of 10 minutes for question answers related to the presentation. Be
prepared for presenting systematic details, if asked by the inspector. It means first 30 minutes are yours and
further extension may not be requested by you. The same time, you should be ready to explore further on a single
click upon inspector interest or concern or question. I will suggest hyperlinks of every potential area of questions.
These hyperlink presentations must also be concise on one slide (however, detail explanation in simple preferably
pictorial case study or scenario is encouraged to describe in minimum follow up slides). Please do not take much
time in responding question or explaining scenario. The presenter must be knowledgeable, confident and best in
communication skills, no matter he or she is from any department. The underline regulator expectations is to hear
about your organogram, outline of manufacturing facility, control strategy, progressive mode, performance
indicators, resistance to aging of your systems and strength of your overall quality management. Do not make
2. more than 10 slides and do not stay more than 3 minutes on any slide. Avoid writing sentences or reducing font
size and loosing or diverting the subject. Safety is above all economics, never give words or focus the subject to
attract inspector(s) sympathy against any social or regulatory burden you experience in maintaining quality
standards.
Do a lot of homework for opening presentation and be prepared to take part in discussion within the norms of
good and super science. Participate generously in inspection process to achieve the outcome of inspection that is
confidence and trust of inspectors. Respond the inspector confidently in a nice way but do not make the discussion
complex, don’t worry, language of science cannot be mutated or thrown away by anyone. It is my personal advice
for international inspections where structured policies and procedures prevail to govern the inspection process.
Note: This is not written for DRAP authorized current inspection scenarios under practice unfortunately, as it is likely designed against the
regulatory science to deceive public and enjoy the misuse of powers for exploitation. Teachers of Pharmacy Schools & Hospital
Pharmacists (who do not have relevant GMP experience) and more interestingly fresh graduates without suitable knowledge and experience
conduct regulatory inspections of complex pharmaceutical engineering, manufacturing processes, and its facilities within few hours or less
than a day. No one relies on inspection process of DRAP, hundreds of inspections have no value in the world as knowledge and integrity is
indiscriminatingly respected.
Disclaimer: Not the obligation of organization or association from where I belong, It is personal point of view based on decades experience
as regulator and student of regulatory sciences
Feedback: It is current thinking and shared just to trigger and sensitize the importance of opening presentation during inspection process.
All critics, comments and questions will be welcome on obaidali1971@gmail.com